Asset Acquisitions (Details) - USD ($) $ in Thousands			3 Months Ended	6 Months Ended	12 Months Ended
	Jan. 04, 2024	Feb. 27, 2023	Mar. 31, 2024	Jun. 30, 2024	Dec. 31, 2023
Asset Acquisition
Issuance of common stock as consideration for LGC license			$ 18,716
L G Chem Ltd
Asset Acquisition
Aggregate Payment Upon Achievement Of Development And Commercial Milestones	$ 205,000
Purchase consideration	92,400
Cash consideration	40,000
Issuance of stock	20,000
Issuance of common stock as consideration for LGC license	18,700
License agreement consideration payment	$ 40,000
Effective date of the license agreement	18 months
Present value	$ 33,700
L G Chem Ltd | Research and development
Asset Acquisition
Purchase consideration				$ 92,400
L G Chem Ltd | Selling, general and administrative
Asset Acquisition
Acquisition related costs	$ 800
Xinvento B.V.
Asset Acquisition
Aggregate Payment Upon Achievement Of Development And Commercial Milestones		$ 206,000
Clinical development milestone payments		6,000
Regulatory approval and commercial milestones milestone payments		125,000
Sales milestone payments		75,000
Purchase consideration		5,667
Cash consideration		4,520
Holdback, payable on the one-year anniversary of the acquisition		500
Acquisition related costs		$ 647
Xinvento B.V. | Research and development
Asset Acquisition
Purchase consideration					$ 5,667